Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 669-677

  Ayyoub, Maha ^a   Zippelius, Alfred ^a   Pittet, Mikaël J ^a   Rimoldi, Donata ^b   Valmori, Danila ^a   Cerottini, Jean Charles ^a,b   Romero, Pedro ^a   Lejeune, Ferdy ^a   Liénard, Danielle ^a   Speiser, Daniel E ^a,c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; MELAN A; MELAN A DERIVATIVE; MELANOMA ANTIGEN; SAPONIN DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; CASE REPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOTHERAPY; INJECTION PAIN; LYMPHADENECTOMY; LYMPHOCYTE CLONE; MELANOMA; MELANOMA CELL; MEMORY CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN STRUCTURE; SENTINEL LYMPH NODE; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; VACCINATION;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; LYMPH NODES; LYMPHOCYTE ACTIVATION; MELANOMA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0037312502     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Old, L. J. Cancer, Tumor immunology: the first century. Curr. Opin. Immunol., 4: 603-607, 1992.
2. Boon, T., Cerottini, J-C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
3. Pardoll, D. M. Cancer vaccines. Nat. Med., 4: 525-531, 1998.
4. Sogn, J. A. Tumor immunology: the glass is half full. Immunity, 9: 757-763, 1998.
5. Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity, 10: 281-287, 1999.
6. Gilboa, E. The makings of a tumor rejection antigen. Immunity, 11: 263-270, 1999.
7. Cohen, E. P., and Kim, T. S. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol., 5: 419-428, 1994.
8. Cromme, F. V., Airey, J., Heemels, M-T., Ploegh, H. L., Keating, P. J., Stern, P. L., Meijer, C. J. L. M., and Walboomers, J. M. M. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med., 179: 335-340, 1994.
9. Ferrone, S., and Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today, 16: 487-494, 1995.
10. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer, 66: 470-476, 1996.
11. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J. J., Lopez-Botet, M., Duggan-Keen, M., and Stern, P. L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today, 18: 89-95, 1997.
12. Hu, X., Chakraborty, N. G., Sporn, J. R., Kurtzman, S. H., Ergin, M. T., and Mukherji, B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res. 56: 2479-2483, 1996.
13. Jäger, E., Bernhard, H., Romero, P., Ringhoffer, M., Arand, M., Karbach, J., Ilsemann, C., Hagedorn, M., and Knuth, A. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo, implications for tumor vaccines with melanoma associated antigens. Int. J. Cancer, 66: 162-169, 1996.
14. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
15. Wang, F., Bade, E., Kuniyoshi, C., Spears, L., Jeffery, G., Marty, V., Groshen, S., and Weber, J. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin. Cancer Res., 5: 2756-2765, 1999.
16. Marchand, M., Van Baren, N., Weynants, P., Brichard, V., Dréno, B., Tessier, M. H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Liénard, D., Beauduin, M., Dietrich, P-Y., Russo, V., Kerger, J., Masucci, G., Jäger, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P. G., van der Bruggen, P., and Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 80: 219-230, 1999.
17. Zinkernagel, R. M., and Hengartner, H. Antiviral immunity. Immunol. Today, 18: 258-260, 1997.
18. Jin, X., Demoitie, M. A., Donahoe, S. M., Ogg, G. S., Bonhoeffer, S., Kakimoto, W. M., Gillespie, G., Moss, P. A., Dyer, W., Kurilla, M. G., Riddell, S. R., Downie, J., Sullivan, J. S., McMichael, A. J., Workman, C., and Nixon, D. F. High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. J. Infect. Dis., 181: 165-175, 2000.
19. Speiser, D. E., and Ohashi, P. S. Activation of cytotoxic T cells by solid tumours? Cell Mol. Life Sci., 54: 263-271, 1998.
20. Restifo, N. P., and Overwijk, W. W. Creating therapeutic cancer vaccines: notes from the battlefield. Immunol. Today, 22: 5-7, 2001.
21. Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Hengartner, H., and Zinkernagel, R. M. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature (Lond.), 411: 1058-1064, 2001.
22. Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified HLA-A*0201-binding residues. J. Immunol., 157: 2539-2548, 1996.
23. Valmori, D., Fonteneau, J. F., Marañón Lizana, C., Gervois, N., Liénard, D., Rimoldi, D., Jongeneel, C. V., Jotereau, F., Cerottini, J-C., and Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogs. J. Immunol., 160: 1750-1758, 1998.
24. Men, Y., Miconnet, I., Valmori, D., Rimoldi, D., Cerottini, J-C., and Romero, P. Assessment of immunogenicity of human Melan-A peptide analogs in HLA-A*0201/Kb transgenic mice. J. Immunol., 162: 3566-3573, 1999.
25. Speiser, D. E., Kyburz, D., Stübi, U., Hengartner, H., and Zinkernagel, R. M. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities: low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide coated target cells but not for in vivo protection. J. Immunol., 149: 972-980, 1992.
26. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M. J., Ogg, G. S., Rimoldi, D., Chen, J. L., Liénard, D., Cerottini, J-C., and Cerundolo, V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytotoxic T lymphocytes. J. Exp. Med., 188: 1641-1650, 1998.
27. Dunbar, P. R., Smith, C. L., Chao, D., Salio, M., Shepherd, D., Mirza, F., Lipp, M., Lanzavecchia, A., Sallusto, F., Evans, A., Russell-Jones, R., Harris, A. L., and Cerundolo, V. A shift in the phenotype of Melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J. Immunol., 165: 6644-6652, 2000.
28. Bostick, P. J., Morton, D. L., Turner, R. R., Huynh, K. T., Wang, H. J., Elashoff, R., Essner, R., and Hoon, D. S. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J. Clin. Oncol., 17: 3238-3244, 1999.
29. Morton, D. L., Wen, D. R., Wong, J. H., Economou, J. S., Cagle, L. A., Storm, F. K., Foshag, L. J., and Cochran, A. J. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg., 127: 392-399, 1992.
30. Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (Lond.), 401: 708-712, 1999.
31. Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Wash. DC), 274: 94-96, 1996.
32. Merkenschlager, M., and Beverley, P. C. Evidence for differential expression of CD45 isoforms by precursors for memory-dependent and independent cytotoxic responses: human CD8 memory CTLp selectively express CD45RO (UCHL1). Int. Immunol., 1: 450-459, 1989.
33. Azuma, M., Phillips, J. H., and Lanier, L. L. CD28-T lymphocytes. Antigenic and functional properties. J. Immunol., 150: 1147-1159, 1993.
34. Hamann, D., Baars, P. A., Rep, M. H., Hooibrink, B., Kerkhof-Garde, S. R., Klein, M. R., and van Lier, R. A. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med., 186: 1407-1418, 1997.
35. Bell, E. B., Sparshott, S. M., and Bunce, C. CD4+ T-cell memory. CD45R subsets and the persistence of antigen: a unifying concept. Immunol. Today, 19: 60-64, 1998.
36. Champagne, P., Ogg, G. S., King, A. S., Knabenhans, C., Ellefsen, K., Nobile, M., Appay, V., Rizzardi, G. P., Fleury, S., Lipp, M., Forster, R., Rowland-Jones, S., Sekaly, R. P., McMichael, A. J., and Pantaleo, G. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (Lond.), 410: 106-111, 2001.
37. Speiser, D. E., Liénard, D., Pittet, M. J., Batard, P., Guillaume, P., Lejeune, F., Cerottini, J.-C., and Romero, P. In vivo activation of melanoma specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus specific T cells. Eur. J. Immunol., 32: 731-741, 2001.
38. Pittet, M. J., Valmori, D., Dunbar, P. R., Speiser, D. E., Liénard, D., Lejeune, F., Fleischhauer, K., Cerundolo, V., Cerottini, J-C., and Romero, P. High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med., 190: 705-715, 1999.
39. Zippelius, A., Pittet, M. J., Batard, P., Ruler, N., de Smedt, M., Guillaume, P., Ellefsen, K., Valmori, D., Liénard, D., Plum, J., Mac-Donald, H. R., Speiser, D. E., Cerottini, J-C., and Romero, P. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J. Exp. Med., 195: 485-494, 2002.
40. McMichael, A. Cytotoxic T lymphocytes specific for influenza virus. Curr. Top Microbiol. Immunol., 189: 75-91, 1994.
41. Dutoit, V., Rubio-Godoy, V., Pittet, M. J., Zippelius, A., Dietrich, P. Y., Legal, F. A., Guillaume, P., Romero, P., Cerottini, J. C., Houghten, R. A., Pinilla, C., and Valmori, D. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J. Exp. Med., 196: 207-216, 2002.
42. Sliz, P., Michielin, O., Cerottini, J-C., Luescher, I., Romero, P., Karplus, M., and Wiley, D. C. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J. Immunol., 167: 3276-3284, 2001.
43. Jäger, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., Jäger, D., Ilsemann, C., Hagedorn, M., Oesch, F., and Knuth, A. Granulocyte-macrophage-colony-stimulating-factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer, 67: 54-62, 1996.
44. Cormier, J. N., Salgaller. M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am., 3: 37-44, 1997.
45. Yamshchikov, G. V., Barnd, D. L., Eastham, S., Galavotti, H., Patterson, J. W., Deacon, D. H., Teates, D., Neese, P., Grosh, W. W., Petroni, G., Engelhard, V. H., and Slingluff, C. L., Jr. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int. J. Cancer, 92: 703-711, 2001.
46. Forster, R., Schubel, A., Breiffeld, D., Kremmer, E., Renner-Muller, I., Wolf, E., and Lipp, M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell, 99: 23-33, 1999.
47. Krieg, A. M. Now I know my CpGs. Trends Microbiol., 9: 249-252, 2001.
48. Kaisho, T., and Akira, S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol., 22: 78-83, 2001.
49. Grewal, I. S., and Flavell, R. A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol., 16: 111-135, 1998.
50. van Kooten, C., and Banchereau, J. CD40-CD40 ligand. J. Leukoc. Biol., 67: 2-17, 2000.
51. Akira, S., Takeda, K., and Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol., 2: 675-680, 2001.
52. Bendelac, A., and Medzhitov, R. Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity. J. Exp. Med., 195: 19-23, 2002.